<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03775213</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00101109</org_study_id>
    <secondary_id>4R00CA207872-03</secondary_id>
    <nct_id>NCT03775213</nct_id>
  </id_info>
  <brief_title>Communication of Personalized Cancer Risk</brief_title>
  <official_title>The Mathematics of Breast Cancer Overtreatment: Improving Treatment Choice Through Effective Communication of Personalized Cancer Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to develop a personalized decision support tool that
      will maximize informed decision-making and minimize overtreatment in patients diagnosed with
      ductal carcinoma in situ (DCIS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptance of active surveillance</measure>
    <time_frame>Up to 1 hour</time_frame>
    <description>Participants will report the probability of choosing active surveillance for their hypothetical diagnosis using a sliding visual scale; probability &gt;50% will be classified as AS acceptance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preferred management choice</measure>
    <time_frame>Up to 1 hour</time_frame>
    <description>Participants report their preferred management choice among the following options: active surveillance, lumpectomy, lumpectomy with radiation, mastectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decision aid acceptability</measure>
    <time_frame>Up to 1 hour</time_frame>
    <description>Acceptability of the decision aid is measured using an existing validated tool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comprehension of key decision aid content</measure>
    <time_frame>Up to 1 hour</time_frame>
    <description>Understanding of key decision aid content is measured using an existing validated tool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decisional conflict</measure>
    <time_frame>Up to 1 hour</time_frame>
    <description>Decisional conflict is measured using an existing validated tool.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Ductal Carcinoma in Situ</condition>
  <arm_group>
    <arm_group_label>Standard Materials + Decision Aid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive standard materials used to communicate DCIS management choices, plus a decision aid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Materials</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants receive standard materials used to communicate DCIS management choices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Decision Aid</intervention_name>
    <description>The decision aid will communicate trade-offs for different management strategies for DCIS, including active surveillance and active treatment.</description>
    <arm_group_label>Standard Materials + Decision Aid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sex: Female

          -  Age: 50-79 years

          -  Has had a negative mammographic screen in the past 2 months

          -  No personal history of breast cancer

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc D Ryser, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Grant, MPH</last_name>
    <phone>9196135953</phone>
    <email>jennifer.grant@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke Mammography Clinic</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Grant, MPH</last_name>
      <phone>919-613-5953</phone>
      <email>jennifer.grant@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Marc Ryser, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 11, 2018</study_first_submitted>
  <study_first_submitted_qc>December 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2018</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ductal carcinoma in situ</keyword>
  <keyword>Decision support tool</keyword>
  <keyword>Informed decision-making</keyword>
  <keyword>Overtreatment</keyword>
  <keyword>Active surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

